The Immunotherapy Cemiplimab for Advanced Squamous Cell Skin Cancer

Except in northern countries, skin cancers are the most common cancers, accounting for approximately half of all cases. Most skin cancers' metastatic potential is low, and they are often detected early. By cells of origin, they are generally divided into melanoma (arising from pigment-producing melanocytes) and nonmelanoma types, with around %95 being nonmelanoma. The common nonmelanoma types are basal cell cancer and squamous cell cancer as the 2 main types. Sunlight is the main risk factor for all skin cancers.
The figure below: The 3 most common skin cancer types, a normal mole and their features:

Most nonmelanoma skin cancers can be successfully treated with simple approaches such as cryotherapy (freezing), curettage and electrodesiccation, topical creams (fluorouracil, imiquimod), or surgical removal. More advanced tumors generally require more extensive surgery or radiotherapy to control local disease adequately.
Because most skin cancers are diagnosed early, the main and most common treatment is surgical removal with some surrounding healthy tissue. Surgery is usually sufficient for basal and squamous cell cancers, although basal cell cancer particularly tends to recur locally. For these nonmelanoma cancers, advanced-stage treatment options are limited and while only one approved treatment exists for advanced basal cell cancer (sonidegib), no approved treatment exists for advanced squamous cell skin cancer.
Basal cell cancers rarely metastasize, while around %5 of squamous cell skin cancers spread to regional lymph nodes and distant organs.
Following this brief overview of skin cancers, we will discuss a first promising systemic treatment for advanced squamous cell skin cancer, described in the article dated 26 July 2018 in NEJM as the journal. A new immunotherapy drug, the PD-1 inhibitor cemiplimab molecule, was tested in a phase 1-2 clinical trialand produced meaningful responses in half the patients.
- In the expanded phase-1 study, of 26 evaluated patients, 13 responded to cemiplimab (%50).
- Stage 4 patients, totaling 59, joined the phase-2 study, with 28 responses (%47).
- The stage 4 phase-2 group was followed for a median of 7.9 months.
- Of the 28 responders, %57 maintained responses for more than 6 months, and at data analysis %82 continued cemiplimab.
- In phase-2 patients, %15 experienced grade 2 or more severe immunotherapy adverse effects as observed (diarrhea, fatigue, nausea, constipation and rash). Treatment stopped due to adverse effects in %7.
- Because most patients continued responding, median progression-free survival (the time treatment keeps disease controlled) and overall survival data have not yet been published.
In conclusion, half the advanced squamous cell skin cancer patients in this study benefited meaningfully from cemiplimab. Adverse effects were generally similar to typical immunotherapy effects, less frequent and manageable. We consider this study highly meaningful for a disease lacking approved advanced-stage treatment. We will follow and share phase-3 results.
*
Sources
PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma.
N Engl J Med, July 2018.
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.